Last updated on October 2018

Study of Ibrutinib and Rituximab in Treatment Na ve Follicular Lymphoma


Brief description of study

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment nave subjects with follicular lymphoma.

Clinical Study Identifier: NCT02947347

Contact Investigators or Research Sites near you

Start Over

Silvie Aarts

ICO L'Hospitalet
Barcelona, Spain
  Connect »

Silvie Aarts

Hospital del Mar
Barcelona, Spain
  Connect »

Silvie Aarts

Hospital Universitario Germans Trias i Pujol
Barcelona, Spain
  Connect »